Home > > > Report Detail

Global Type 1 Diabetes (T1D) Market Research Report 2023

Publisher Name :
Date: 07-Feb-2023
No. of pages: 91
Inquire Before Buying

Type 1 diabetes (T1D) is an autoimmune disease that occurs when a person's pancreas stops producing insulin, the hormone that controls blood-sugar levels. T1D develops when the insulin-producing pancreatic beta cells are mistakenly destroyed by the body's immune system. The cause of this attack is still being researched, however scientists believe the cause may have genetic and environmental components.

Highlights

The global Type 1 Diabetes (T1D) market was valued at US$ 1901.2 million in 2022 and is anticipated to reach US$ 2685.2 million by 2029, witnessing a CAGR of 4.6% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.

Sedentary lifestyle, unhealthy diet, lack of exercise and increasing prevalence of diabetes are key driver for Type 1 Diabetes (T1D) market. Insulin therapy is very much essential in the patients who have type 1 diabetes. Rising launch of the novel insulin formulations along with several adjunct therapies will positively impact the insulin acceptance. On the other hand, this chronic disorder poses a significant economic impact owing to the increasing cost of insulin coupled with other conditions such as cardiac disorders, kidney disease among others. While insulin therapy keeps people with T1D alive and can help keep blood-glucose levels within recommended range, it is not a cure, nor does it prevent the possibility of T1D's serious effects. Although T1D is a serious and challenging disease, long-term management options continue to evolve, allowing those with T1D to have full and active lives. Asia Pacific region recorded the highest growth rate over the forecast period owing to the increasingly sedentary lifestyles, obese population, and improper food habits. North America accounted for more than 50% of the total market share over the forecast period.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Type 1 Diabetes (T1D), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Type 1 Diabetes (T1D).

The Type 1 Diabetes (T1D) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Type 1 Diabetes (T1D) market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Type 1 Diabetes (T1D) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.

By Company

- Novo Nordisk

- Sanofi

- Eli Lilly

- Merck

- Boehringer Ingelheim

- Samsung Bioepis

- Biocon

- Astellas

- Janssen

- Bristol-Myers Squibb

- Lexicon

- Sanofi

Segment by Type

- Rapid Acting Insulin Analogs

- Long Acting Insulin Analogs

- Premix Insulin Analogs

Segment by Application

- Children

- Adults

Consumption by Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- - Philippines

- - Vietnam

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - U.A.E

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Detailed analysis of Type 1 Diabetes (T1D) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Sales, revenue of Type 1 Diabetes (T1D) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 9: The main points and conclusions of the report.

Global Type 1 Diabetes (T1D) Market Research Report 2023

Table of Contents
1 Type 1 Diabetes (T1D) Market Overview
1.1 Product Overview and Scope of Type 1 Diabetes (T1D)
1.2 Type 1 Diabetes (T1D) Segment by Type
1.2.1 Global Type 1 Diabetes (T1D) Market Value Comparison by Type (2023-2029)
1.2.2 Rapid Acting Insulin Analogs
1.2.3 Long Acting Insulin Analogs
1.2.4 Premix Insulin Analogs
1.3 Type 1 Diabetes (T1D) Segment by Application
1.3.1 Global Type 1 Diabetes (T1D) Market Value by Application: (2023-2029)
1.3.2 Children
1.3.3 Adults
1.4 Global Type 1 Diabetes (T1D) Market Size Estimates and Forecasts
1.4.1 Global Type 1 Diabetes (T1D) Revenue 2018-2029
1.4.2 Global Type 1 Diabetes (T1D) Sales 2018-2029
1.4.3 Global Type 1 Diabetes (T1D) Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Type 1 Diabetes (T1D) Market Competition by Manufacturers
2.1 Global Type 1 Diabetes (T1D) Sales Market Share by Manufacturers (2018-2023)
2.2 Global Type 1 Diabetes (T1D) Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Type 1 Diabetes (T1D) Average Price by Manufacturers (2018-2023)
2.4 Global Type 1 Diabetes (T1D) Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Type 1 Diabetes (T1D), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Type 1 Diabetes (T1D), Product Type & Application
2.7 Type 1 Diabetes (T1D) Market Competitive Situation and Trends
2.7.1 Type 1 Diabetes (T1D) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Type 1 Diabetes (T1D) Players Market Share by Revenue
2.7.3 Global Type 1 Diabetes (T1D) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Type 1 Diabetes (T1D) Retrospective Market Scenario by Region
3.1 Global Type 1 Diabetes (T1D) Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Type 1 Diabetes (T1D) Global Type 1 Diabetes (T1D) Sales by Region: 2018-2029
3.2.1 Global Type 1 Diabetes (T1D) Sales by Region: 2018-2023
3.2.2 Global Type 1 Diabetes (T1D) Sales by Region: 2024-2029
3.3 Global Type 1 Diabetes (T1D) Global Type 1 Diabetes (T1D) Revenue by Region: 2018-2029
3.3.1 Global Type 1 Diabetes (T1D) Revenue by Region: 2018-2023
3.3.2 Global Type 1 Diabetes (T1D) Revenue by Region: 2024-2029
3.4 North America Type 1 Diabetes (T1D) Market Facts & Figures by Country
3.4.1 North America Type 1 Diabetes (T1D) Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Type 1 Diabetes (T1D) Sales by Country (2018-2029)
3.4.3 North America Type 1 Diabetes (T1D) Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Type 1 Diabetes (T1D) Market Facts & Figures by Country
3.5.1 Europe Type 1 Diabetes (T1D) Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Type 1 Diabetes (T1D) Sales by Country (2018-2029)
3.5.3 Europe Type 1 Diabetes (T1D) Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Type 1 Diabetes (T1D) Market Facts & Figures by Country
3.6.1 Asia Pacific Type 1 Diabetes (T1D) Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Type 1 Diabetes (T1D) Sales by Country (2018-2029)
3.6.3 Asia Pacific Type 1 Diabetes (T1D) Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Type 1 Diabetes (T1D) Market Facts & Figures by Country
3.7.1 Latin America Type 1 Diabetes (T1D) Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Type 1 Diabetes (T1D) Sales by Country (2018-2029)
3.7.3 Latin America Type 1 Diabetes (T1D) Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Type 1 Diabetes (T1D) Market Facts & Figures by Country
3.8.1 Middle East and Africa Type 1 Diabetes (T1D) Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Type 1 Diabetes (T1D) Sales by Country (2018-2029)
3.8.3 Middle East and Africa Type 1 Diabetes (T1D) Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Type 1 Diabetes (T1D) Sales by Type (2018-2029)
4.1.1 Global Type 1 Diabetes (T1D) Sales by Type (2018-2023)
4.1.2 Global Type 1 Diabetes (T1D) Sales by Type (2024-2029)
4.1.3 Global Type 1 Diabetes (T1D) Sales Market Share by Type (2018-2029)
4.2 Global Type 1 Diabetes (T1D) Revenue by Type (2018-2029)
4.2.1 Global Type 1 Diabetes (T1D) Revenue by Type (2018-2023)
4.2.2 Global Type 1 Diabetes (T1D) Revenue by Type (2024-2029)
4.2.3 Global Type 1 Diabetes (T1D) Revenue Market Share by Type (2018-2029)
4.3 Global Type 1 Diabetes (T1D) Price by Type (2018-2029)
5 Segment by Application
5.1 Global Type 1 Diabetes (T1D) Sales by Application (2018-2029)
5.1.1 Global Type 1 Diabetes (T1D) Sales by Application (2018-2023)
5.1.2 Global Type 1 Diabetes (T1D) Sales by Application (2024-2029)
5.1.3 Global Type 1 Diabetes (T1D) Sales Market Share by Application (2018-2029)
5.2 Global Type 1 Diabetes (T1D) Revenue by Application (2018-2029)
5.2.1 Global Type 1 Diabetes (T1D) Revenue by Application (2018-2023)
5.2.2 Global Type 1 Diabetes (T1D) Revenue by Application (2024-2029)
5.2.3 Global Type 1 Diabetes (T1D) Revenue Market Share by Application (2018-2029)
5.3 Global Type 1 Diabetes (T1D) Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Corporation Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Novo Nordisk Type 1 Diabetes (T1D) Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Corporation Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Sanofi Type 1 Diabetes (T1D) Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 Eli Lilly
6.3.1 Eli Lilly Corporation Information
6.3.2 Eli Lilly Description and Business Overview
6.3.3 Eli Lilly Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Eli Lilly Type 1 Diabetes (T1D) Product Portfolio
6.3.5 Eli Lilly Recent Developments/Updates
6.4 Merck
6.4.1 Merck Corporation Information
6.4.2 Merck Description and Business Overview
6.4.3 Merck Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Merck Type 1 Diabetes (T1D) Product Portfolio
6.4.5 Merck Recent Developments/Updates
6.5 Boehringer Ingelheim
6.5.1 Boehringer Ingelheim Corporation Information
6.5.2 Boehringer Ingelheim Description and Business Overview
6.5.3 Boehringer Ingelheim Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Boehringer Ingelheim Type 1 Diabetes (T1D) Product Portfolio
6.5.5 Boehringer Ingelheim Recent Developments/Updates
6.6 Samsung Bioepis
6.6.1 Samsung Bioepis Corporation Information
6.6.2 Samsung Bioepis Description and Business Overview
6.6.3 Samsung Bioepis Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Samsung Bioepis Type 1 Diabetes (T1D) Product Portfolio
6.6.5 Samsung Bioepis Recent Developments/Updates
6.7 Biocon
6.6.1 Biocon Corporation Information
6.6.2 Biocon Description and Business Overview
6.6.3 Biocon Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Biocon Type 1 Diabetes (T1D) Product Portfolio
6.7.5 Biocon Recent Developments/Updates
6.8 Astellas
6.8.1 Astellas Corporation Information
6.8.2 Astellas Description and Business Overview
6.8.3 Astellas Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Astellas Type 1 Diabetes (T1D) Product Portfolio
6.8.5 Astellas Recent Developments/Updates
6.9 Janssen
6.9.1 Janssen Corporation Information
6.9.2 Janssen Description and Business Overview
6.9.3 Janssen Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Janssen Type 1 Diabetes (T1D) Product Portfolio
6.9.5 Janssen Recent Developments/Updates
6.10 Bristol-Myers Squibb
6.10.1 Bristol-Myers Squibb Corporation Information
6.10.2 Bristol-Myers Squibb Description and Business Overview
6.10.3 Bristol-Myers Squibb Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Bristol-Myers Squibb Type 1 Diabetes (T1D) Product Portfolio
6.10.5 Bristol-Myers Squibb Recent Developments/Updates
6.11 Lexicon
6.11.1 Lexicon Corporation Information
6.11.2 Lexicon Type 1 Diabetes (T1D) Description and Business Overview
6.11.3 Lexicon Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Lexicon Type 1 Diabetes (T1D) Product Portfolio
6.11.5 Lexicon Recent Developments/Updates
6.12 Sanofi
6.12.1 Sanofi Corporation Information
6.12.2 Sanofi Type 1 Diabetes (T1D) Description and Business Overview
6.12.3 Sanofi Type 1 Diabetes (T1D) Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Sanofi Type 1 Diabetes (T1D) Product Portfolio
6.12.5 Sanofi Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Type 1 Diabetes (T1D) Industry Chain Analysis
7.2 Type 1 Diabetes (T1D) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Type 1 Diabetes (T1D) Production Mode & Process
7.4 Type 1 Diabetes (T1D) Sales and Marketing
7.4.1 Type 1 Diabetes (T1D) Sales Channels
7.4.2 Type 1 Diabetes (T1D) Distributors
7.5 Type 1 Diabetes (T1D) Customers
8 Type 1 Diabetes (T1D) Market Dynamics
8.1 Type 1 Diabetes (T1D) Industry Trends
8.2 Type 1 Diabetes (T1D) Market Drivers
8.3 Type 1 Diabetes (T1D) Market Challenges
8.4 Type 1 Diabetes (T1D) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Type 1 Diabetes (T1D) Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Type 1 Diabetes (T1D) Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Type 1 Diabetes (T1D) Market Competitive Situation by Manufacturers in 2022
Table 4. Global Type 1 Diabetes (T1D) Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Type 1 Diabetes (T1D) Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Type 1 Diabetes (T1D) Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Type 1 Diabetes (T1D) Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Type 1 Diabetes (T1D) Average Price (USD/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Type 1 Diabetes (T1D), Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Type 1 Diabetes (T1D), Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Type 1 Diabetes (T1D), Product Type & Application
Table 12. Global Key Manufacturers of Type 1 Diabetes (T1D), Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Type 1 Diabetes (T1D) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Type 1 Diabetes (T1D) as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Type 1 Diabetes (T1D) Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Type 1 Diabetes (T1D) Sales by Region (2018-2023) & (K Units)
Table 18. Global Type 1 Diabetes (T1D) Sales Market Share by Region (2018-2023)
Table 19. Global Type 1 Diabetes (T1D) Sales by Region (2024-2029) & (K Units)
Table 20. Global Type 1 Diabetes (T1D) Sales Market Share by Region (2024-2029)
Table 21. Global Type 1 Diabetes (T1D) Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Type 1 Diabetes (T1D) Revenue Market Share by Region (2018-2023)
Table 23. Global Type 1 Diabetes (T1D) Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Type 1 Diabetes (T1D) Revenue Market Share by Region (2024-2029)
Table 25. North America Type 1 Diabetes (T1D) Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Type 1 Diabetes (T1D) Sales by Country (2018-2023) & (K Units)
Table 27. North America Type 1 Diabetes (T1D) Sales by Country (2024-2029) & (K Units)
Table 28. North America Type 1 Diabetes (T1D) Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Type 1 Diabetes (T1D) Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Type 1 Diabetes (T1D) Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Type 1 Diabetes (T1D) Sales by Country (2018-2023) & (K Units)
Table 32. Europe Type 1 Diabetes (T1D) Sales by Country (2024-2029) & (K Units)
Table 33. Europe Type 1 Diabetes (T1D) Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Type 1 Diabetes (T1D) Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Type 1 Diabetes (T1D) Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Type 1 Diabetes (T1D) Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Type 1 Diabetes (T1D) Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Type 1 Diabetes (T1D) Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Type 1 Diabetes (T1D) Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Type 1 Diabetes (T1D) Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Type 1 Diabetes (T1D) Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Type 1 Diabetes (T1D) Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Type 1 Diabetes (T1D) Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Type 1 Diabetes (T1D) Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Type 1 Diabetes (T1D) Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Type 1 Diabetes (T1D) Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Type 1 Diabetes (T1D) Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Type 1 Diabetes (T1D) Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Type 1 Diabetes (T1D) Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Type 1 Diabetes (T1D) Sales (K Units) by Type (2018-2023)
Table 51. Global Type 1 Diabetes (T1D) Sales (K Units) by Type (2024-2029)
Table 52. Global Type 1 Diabetes (T1D) Sales Market Share by Type (2018-2023)
Table 53. Global Type 1 Diabetes (T1D) Sales Market Share by Type (2024-2029)
Table 54. Global Type 1 Diabetes (T1D) Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Type 1 Diabetes (T1D) Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Type 1 Diabetes (T1D) Revenue Market Share by Type (2018-2023)
Table 57. Global Type 1 Diabetes (T1D) Revenue Market Share by Type (2024-2029)
Table 58. Global Type 1 Diabetes (T1D) Price (USD/Unit) by Type (2018-2023)
Table 59. Global Type 1 Diabetes (T1D) Price (USD/Unit) by Type (2024-2029)
Table 60. Global Type 1 Diabetes (T1D) Sales (K Units) by Application (2018-2023)
Table 61. Global Type 1 Diabetes (T1D) Sales (K Units) by Application (2024-2029)
Table 62. Global Type 1 Diabetes (T1D) Sales Market Share by Application (2018-2023)
Table 63. Global Type 1 Diabetes (T1D) Sales Market Share by Application (2024-2029)
Table 64. Global Type 1 Diabetes (T1D) Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Type 1 Diabetes (T1D) Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Type 1 Diabetes (T1D) Revenue Market Share by Application (2018-2023)
Table 67. Global Type 1 Diabetes (T1D) Revenue Market Share by Application (2024-2029)
Table 68. Global Type 1 Diabetes (T1D) Price (USD/Unit) by Application (2018-2023)
Table 69. Global Type 1 Diabetes (T1D) Price (USD/Unit) by Application (2024-2029)
Table 70. Novo Nordisk Corporation Information
Table 71. Novo Nordisk Description and Business Overview
Table 72. Novo Nordisk Type 1 Diabetes (T1D) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 73. Novo Nordisk Type 1 Diabetes (T1D) Product
Table 74. Novo Nordisk Recent Developments/Updates
Table 75. Sanofi Corporation Information
Table 76. Sanofi Description and Business Overview
Table 77. Sanofi Type 1 Diabetes (T1D) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 78. Sanofi Type 1 Diabetes (T1D) Product
Table 79. Sanofi Recent Developments/Updates
Table 80. Eli Lilly Corporation Information
Table 81. Eli Lilly Description and Business Overview
Table 82. Eli Lilly Type 1 Diabetes (T1D) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 83. Eli Lilly Type 1 Diabetes (T1D) Product
Table 84. Eli Lilly Recent Developments/Updates
Table 85. Merck Corporation Information
Table 86. Merck Description and Business Overview
Table 87. Merck Type 1 Diabetes (T1D) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 88. Merck Type 1 Diabetes (T1D) Product
Table 89. Merck Recent Developments/Updates
Table 90. Boehringer Ingelheim Corporation Information
Table 91. Boehringer Ingelheim Description and Business Overview
Table 92. Boehringer Ingelheim Type 1 Diabetes (T1D) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 93. Boehringer Ingelheim Type 1 Diabetes (T1D) Product
Table 94. Boehringer Ingelheim Recent Developments/Updates
Table 95. Samsung Bioepis Corporation Information
Table 96. Samsung Bioepis Description and Business Overview
Table 97. Samsung Bioepis Type 1 Diabetes (T1D) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 98. Samsung Bioepis Type 1 Diabetes (T1D) Product
Table 99. Samsung Bioepis Recent Developments/Updates
Table 100. Biocon Corporation Information
Table 101. Biocon Description and Business Overview
Table 102. Biocon Type 1 Diabetes (T1D) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 103. Biocon Type 1 Diabetes (T1D) Product
Table 104. Biocon Recent Developments/Updates
Table 105. Astellas Corporation Information
Table 106. Astellas Description and Business Overview
Table 107. Astellas Type 1 Diabetes (T1D) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 108. Astellas Type 1 Diabetes (T1D) Product
Table 109. Astellas Recent Developments/Updates
Table 110. Janssen Corporation Information
Table 111. Janssen Description and Business Overview
Table 112. Janssen Type 1 Diabetes (T1D) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 113. Janssen Type 1 Diabetes (T1D) Product
Table 114. Janssen Recent Developments/Updates
Table 115. Bristol-Myers Squibb Corporation Information
Table 116. Bristol-Myers Squibb Description and Business Overview
Table 117. Bristol-Myers Squibb Type 1 Diabetes (T1D) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 118. Bristol-Myers Squibb Type 1 Diabetes (T1D) Product
Table 119. Bristol-Myers Squibb Recent Developments/Updates
Table 120. Lexicon Corporation Information
Table 121. Lexicon Description and Business Overview
Table 122. Lexicon Type 1 Diabetes (T1D) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 123. Lexicon Type 1 Diabetes (T1D) Product
Table 124. Lexicon Recent Developments/Updates
Table 125. Sanofi Corporation Information
Table 126. Sanofi Description and Business Overview
Table 127. Sanofi Type 1 Diabetes (T1D) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 128. Sanofi Type 1 Diabetes (T1D) Product
Table 129. Sanofi Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Type 1 Diabetes (T1D) Distributors List
Table 133. Type 1 Diabetes (T1D) Customers List
Table 134. Type 1 Diabetes (T1D) Market Trends
Table 135. Type 1 Diabetes (T1D) Market Drivers
Table 136. Type 1 Diabetes (T1D) Market Challenges
Table 137. Type 1 Diabetes (T1D) Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Type 1 Diabetes (T1D)
Figure 2. Global Type 1 Diabetes (T1D) Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Type 1 Diabetes (T1D) Market Share by Type in 2022 & 2029
Figure 4. Rapid Acting Insulin Analogs Product Picture
Figure 5. Long Acting Insulin Analogs Product Picture
Figure 6. Premix Insulin Analogs Product Picture
Figure 7. Global Type 1 Diabetes (T1D) Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Type 1 Diabetes (T1D) Market Share by Application in 2022 & 2029
Figure 9. Children
Figure 10. Adults
Figure 11. Global Type 1 Diabetes (T1D) Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Type 1 Diabetes (T1D) Market Size (2018-2029) & (US$ Million)
Figure 13. Global Type 1 Diabetes (T1D) Sales (2018-2029) & (K Units)
Figure 14. Global Type 1 Diabetes (T1D) Average Price (USD/Unit) & (2018-2029)
Figure 15. Type 1 Diabetes (T1D) Report Years Considered
Figure 16. Type 1 Diabetes (T1D) Sales Share by Manufacturers in 2022
Figure 17. Global Type 1 Diabetes (T1D) Revenue Share by Manufacturers in 2022
Figure 18. The Global 5 and 10 Largest Type 1 Diabetes (T1D) Players: Market Share by Revenue in 2022
Figure 19. Type 1 Diabetes (T1D) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 20. Global Type 1 Diabetes (T1D) Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 21. North America Type 1 Diabetes (T1D) Sales Market Share by Country (2018-2029)
Figure 22. North America Type 1 Diabetes (T1D) Revenue Market Share by Country (2018-2029)
Figure 23. U.S. Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 24. Canada Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Europe Type 1 Diabetes (T1D) Sales Market Share by Country (2018-2029)
Figure 26. Europe Type 1 Diabetes (T1D) Revenue Market Share by Country (2018-2029)
Figure 27. Germany Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. France Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. U.K. Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Italy Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Russia Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Asia Pacific Type 1 Diabetes (T1D) Sales Market Share by Region (2018-2029)
Figure 33. Asia Pacific Type 1 Diabetes (T1D) Revenue Market Share by Region (2018-2029)
Figure 34. China Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Japan Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. South Korea Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. India Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Australia Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Taiwan Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Indonesia Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Thailand Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Malaysia Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Philippines Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Latin America Type 1 Diabetes (T1D) Sales Market Share by Country (2018-2029)
Figure 45. Latin America Type 1 Diabetes (T1D) Revenue Market Share by Country (2018-2029)
Figure 46. Mexico Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Brazil Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Argentina Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Type 1 Diabetes (T1D) Sales Market Share by Country (2018-2029)
Figure 50. Middle East & Africa Type 1 Diabetes (T1D) Revenue Market Share by Country (2018-2029)
Figure 51. Turkey Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. U.A.E Type 1 Diabetes (T1D) Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Global Sales Market Share of Type 1 Diabetes (T1D) by Type (2018-2029)
Figure 55. Global Revenue Market Share of Type 1 Diabetes (T1D) by Type (2018-2029)
Figure 56. Global Type 1 Diabetes (T1D) Price (USD/Unit) by Type (2018-2029)
Figure 57. Global Sales Market Share of Type 1 Diabetes (T1D) by Application (2018-2029)
Figure 58. Global Revenue Market Share of Type 1 Diabetes (T1D) by Application (2018-2029)
Figure 59. Global Type 1 Diabetes (T1D) Price (USD/Unit) by Application (2018-2029)
Figure 60. Type 1 Diabetes (T1D) Value Chain
Figure 61. Type 1 Diabetes (T1D) Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs